---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-008949"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:38:22.918671+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients

## Summary
- FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.
- MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.
- Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated.

## SEC filing metadata
- accession: 0001437749-26-008949
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/0001437749-26-008949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/mbrx20260317_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-008949
- JSON: https://secwatch.observer/filing/0001437749-26-008949.json
- Plain text: https://secwatch.observer/filing/0001437749-26-008949.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/0001437749-26-008949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.